FDA Puts Perifosine On Fast Track For Treatment Of Multiple Myeloma – Perifosine ^[1] (KRX-0401) has received priority for evaluation by the FDA as an anti-cancer agent in the treatment of relapsed/refractory myeloma through the Fast Track program. The Fast Track program expedites the review of new drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs. A Phase 3 clinical trial is planned for the end of the year to investigate the use of perifosine in combination with Velcade ^[2] (bortezomib) and dexamethasone ^[3] (Decadron). For more information, please see the Keryx Biopharmaceuticals ^[4] press release.

Higher Rates Of Multiple Myeloma And Other Cancers Seen In Residents Near Landfill – Researchers for the Central Cancer Registry found significantly higher rates than expected of multiple myeloma and other cancers among residents living near the White Street Landfill and the former E. H. Glass dump site in Greensboro, North Carolina. The study observed that the rate of multiple myeloma from 1990 to 2006 was twice the expected rate.  However, the researchers say that the number of myeloma cases is too small to draw any conclusions. The researchers also maintained that study results do not imply causation nor do they prove that living near the landfills causes health problems. Genetic factors and lifestyle choices could also account for the discrepancy. For more information, please see the Central Cancer Registry ^[5] report.